Preliminary Q1 2026: Sales +12%, Operating Profit +37% YoY
-
Preliminary separate financial results for Q1 2026: Sales KRW 447.7B (+12.2% YoY), Operating profit KRW 17.6B (+36.9% YoY), Net profit KRW 14.9B (+6.3% YoY)
-
Compared to previous quarter (Q4 2025): Sales +5.3%, Operating profit -28.5%, Net profit -55.2%
-
These are preliminary unaudited figures under K-IFRS, subject to change after review
KOSPI Filing Information
-
Filing: Preliminary Operating Results (Fair Disclosure)
-
Company: Chong Kun Dang Pharmaceutical (185750)
-
Submission: Chong Kun Dang Pharmaceutical Corp.
-
Receipt: 04-29-2026
-
Under KRX KOSPI Market Division